ERBB2 and breast carcinoma: Interestingly, HER2-zero breast cancers had worse OS outcomes compared with HER2-positive peers in the hormone receptor-negative patients (univariate analysis, Bonferroni corrected p = 0.080, Supplementary Figure S4B; multivariate analysis, p < 0.001).